Author Archives: Admin

Kraig Biocraft Laboratories Chief Executive Awarded Top 20 Pioneering CEO’s of 2019

ANN ARBOR, Mich., – Sept 13, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its CEO, Kim Thompson, was recently recognized as one of MyTechMag magazine’s top 20 pioneering CEO’s of 2019. In the recent CEO edition, Mr Thompson shares the incredible story of the founding of Kraig Labs, as well as how his outsider status and determination delivered success against overwhelming odds.

In selecting the top 20 pioneering CEO’s of 2019, MyTechMag selection criteria included a review of the complexity of the challenges overcome, the growth of the underlying business, and the CEO’s ability to harness their team’s potential.

“I am honored to have been selected for this recognition. MyTechMag’s award comes on the verge of a very exciting time for Kraig Labs, as we expect to soon be formally launching commercial scale production of our eco-friendly recombinant spider silk,” said CEO and Founder, Thompson. “Kraig Labs has been pioneering the way forward for cost effective spider silk production and today’s recognition of my work and our Company’s role in bringing this innovation to market is an honor. Together, our team has faced and conquered numerous obstacles that stood between us and our goal. In that spirit I accept this award as recognition for the entire Kraig Labs team, including our valued employees and shareholders.”

You can find a copy of the article at Kraiglabs.com or read the full magazine article at MyTechMag.com or read Mr Thompson’s profile

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Selects Finalists for Expanded Board of Directors

ANN ARBOR, Mich., – Sept 12, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has narrowed its list of candidates to seven highly qualified individuals to fill the four additional Board of Directors member positions that the Company plans to appoint as part of its preparations for a potential uplist to a national exchange. The Company has received nearly 200 qualified applications for the new board positions. Senior management, after completing vigorous selection process, has narrowed the field down to seven finalists. These candidates offer a broad and diverse background, ranging from finance and compliance to global operations, marketing, and tech development. This diversity in experience was intentionally curated, by management, to seat a board able to bring wide ranging knowledge and oversight.

The Company is entering its final selection round and anticipates making a determination, and announcing the appointments, of the new board members, within the next three weeks.

“I am very excited about each of our finalists; I know that those who are ultimately selected will strengthen our Company. I would like to thank all of the applicants who took the time to go through the selection process,” said Board Chairman and CEO Kim Thompson.

As discussed and approved, by the Company’s shareholders, during the annual shareholder meeting held in July, the appointment of these new board members is part of the Company efforts to position the company for a potential uplist and to strengthen corporate management and oversight as we prepare for production ramp up.

The Company will issue an announcement of the new board members when the selection process in finalized.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Expands and Strengthens R&D Research Team

Kraig Labs adds first biological engineer to R&D team bringing extensive spider silk experience

ANN ARBOR, Mich., – August 20, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has expanded its team with the addition of its first biological engineer to the R&D department. This new hire brings extensive experience working with spider silks. Working directly with Kraig’s Chief Scientist, she is already developing new and stronger transgenics and providing valuable input shaping the direction the Company’s research is headed.

Her input in protein design combined with the Company’s breakthroughs in accelerating the rate of transgenic achievements should result in rapid prototyping of new and exciting silk materials. As a biological engineer, with a background in spider silk, she fits in very well with the culture of the Company and has already brought innovative ideas to streamline Kraig Labs’ R&D processes. Additionally, she possesses experience with sericulture and has implemented new procedures in the Company’s facility to ensure the continued production of the best quality fibers.

“I am very excited to add an engineer to our molecular biology team. She is extremely impressive with her depth of knowledge and experience with sericulture, recombinant proteins, spider silks, and material properties. She has already made several important contributions to our R&D and I am looking forward to future breakthroughs,” said Chief Scientist, Dr. Trevor Kane. “We were very fortunate to have found a bio-engineer with a background in spider silk and extensive research experience.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories completes construction of Spider Silk Biotech Research Laboratory in Vietnam

ANN ARBOR, Mich., – August 8, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has completed construction of its new biotech research laboratory in Vietnam. The new laboratory suite is located within the Company’s recombinant spider silk production facility in Quang Nam, Vietnam and consists of eleven separate labs. These new labs are a key piece of the Company’s spider silk commercialization program and were part of the, now complete, renovation efforts at the Prodigy Textiles factory, the Company’s wholly owned subsidiary and production arm.

This new laboratory suite was built to support production ramp up and will serve as a testing and quality control facility for the commercialization of the Company’s recombinant spider silk technologies. To ensure compliance with regulations, related to genetically modified technologies, this laboratory was built to the design and specification of the Vietnamese Ministry of Science and Technology (MoST). Moving into the future, the Company anticipates utilizing these new laboratories for the development of future innovations in spider silk fibers and products to compliment the Company’s existing technologies, which are now moving to commercialization.

“With these new laboratories and the completion of the Prodigy Textiles factory renovations, we are now ready to start the transition and expansion of our recombinant spider silk production into the new factory,” said COO Jon Rice. “We purposefully designed our laboratories to mirror those of the MoST, where the initial evaluation and approval of our specialized silkworms were finalized, in order to accelerate our commercial ramp up.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories’ shareholders vote to approve plan to uplist to a national exchange during Annual Shareholder Meeting

Kraig Labs shareholders approve all ballot proposals

ANN ARBOR, Mich., – July 29, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company’s shareholders have voted to approve uplisting to a national securities exchange, during its annual shareholder meeting (“meeting”) held on July 24. Additionally, shareholders overwhelmingly approved all proposed ballot measures.

The meeting attendance greatly exceeded Company management’s expectations, including shareholders from outside of the US in the audience. Originally planned for forty five minutes, the meeting lasted for over three and a half hours, with Company management holding open question and answer sessions during both the formal and informal portions of the meeting.

Kim Thompson, the founder and CEO of Kraig Labs, provided a presentation to shareholders on the significance of the Company strategy to uplist to a national exchange and the underlying efforts the Company has made to prepare for this transition.

Jon Rice, the Company’s COO, shared an overview of the Company’s multiphase production model, progress in the buildout of its overseas factory, and the Company’s go to market strategies leveraging collaborations with leading brands in select market channels.

Several member of the Kraig Labs staff were in attendance at the meeting, including Dr Trevor Kane, the Company’s newly appointed Chief Scientist. Samples of the Company’s recombinant spider silk thread and silkworms, at each stage of the lifecycle, were on display for shareholders to see and touch.

“I believe that today’s shareholder vote and approval of all of the ballot measures puts Kraig Labs on a solid footing for our future growth,” said Thompson. “I would like to personally thank all of our shareholders for their support of the proposals. With their overwhelming support and encouragement we are emboldened to carry forward with our plans to disrupt the textile markets with our eco-friendly and affordable recombinant spider silk.”

Cautionary Statement: While management and shareholders have approved an uplist, there can be no guarantee that these plans will come to fruition. There are a number of obstacles that the Company will have to successfully navigate before an uplist can be implemented.

“The shareholder meeting was an absolute success. It was a pleasure to meet with so many of our shareholders and share our mutual excitement for the future of Kraig Labs,” said COO Jon Rice.

Details of the voting results can be found on the Company’s website, please go to www.KraigLabs.com/sec-filings/

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Responses to frequently asked questions regarding the purpose of shareholder meeting

The following is correspondence between the CEO and two of our shareholders which we believe is informative on the Company’s perspective on ballot initiatives for the upcoming shareholder meeting.

Gary,

Thank you for your input and support.

I just responded to another shareholder’s inquiry and am including my response to him below, as some of his concerns overlap yours and I think are representative of questions and input I have received from a few others.

On the question of the preferred stock, I think your concerns have some merit. Super majorities do have a mixed history. My intention when I received the preferred back in 2013 was to make sure that we always had the votes necessary to execute on our business plan. The thinking at that time was that if there was an opportunity for a significant acquisition, merger or up-list, time would be of the essence. The corporate charter was amended at that time to allow a majority to take such action without a shareholder meeting. The reason was that it takes significant planing, delays and expense to hold a shareholder meeting and a significant opportunity could slip through our hands in that time.

It is a bit ironic then that, now, when we have a possible opportunity for an up-list, we are never the less holding a meeting of shareholders.

My small team is fully taxed preparing for the meeting while keeping everything else afloat and executing on our plans for Vietnam. It is fair to say that I am over-taxed as well. I will keep an open mind about the super majority and seek input from the team and our securities counsel in the coming weeks and months.

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

Zach,

Thank you for your email. I am responding to you directly because it looks like you have done your homework on the history of RS.

I do not doubt the Stern data. Typically when a company does a RS it is because the stock price has been eroding over time and the company can not maintain its exchange listing at the new stock price. While I have not seen any data, it may also be the case that companies enter into a RS because of covenants on their debt interments or under presser from debt holders. Of course such companies have a tendency to under perform. They have a history of under-performance.

For Kraig Labs, that is simply not the case. Our stock has shown significant historical gains (even accounting for the recent pull back) and we are hitting the major milestones we have set for ourselves in terms of setting up production and early stage commercialization. It is that growth which has given us a possible path to a national exchange.

Historically, we have run this Company on very thin financing. Now that we need to ramp up production, thin financing will not allow us to ramp up quickly enough to meet our targets or to satisfy the potential customers that we are talking with.

I can not predict the stock price. I do not know where it is going any more than anyone else. But I do have strong opinions about what it will take to make the Company a success and what it will take to bring our products to market in a manner that will allow us to beat the competition and capture market share. My philosophy has always been to focus on the Company’s fundamentals and executing on our business plan. I do believe that focusing on growing the Company will ultimately benefit our shareholders.

My suggestion would be, that the Stern School data is not as relevant as another set of data. What happens, statistically, to share price and long term shareholder value when an OTC Company up-lists?

Our immediate plan to to shoot for the up-list. There is no guarantee that we will make the up-list. As I see it we have a relatively small window in which to do this and several moving pieces which need to all move through the window at the same time. To be frank, my stress levels in engineering and managing this process are very high. Surprisingly, this is because I think we might just achieve this success and hit the remaining marks in our business plan over the near and medium term. Some times success itself can be a stresser. I think the market feels it too.

I know the recent drop in share price is also stressing you and others. I am personalty affected as well. But I see opportunity and the possibility of growing this small boat into a bigger and stronger ship. I chose growth. While I am stressed, I am also excited and, I must confess, elated.

Thank you for your support and your input. If you chose not to take this ride and see these opportunities through with us I understand. There are risks, which I do not want to minimize. It is no my role, as I see it, to convince people to buy the stock or to maintain their investment. My role it to grow the Company and put in place a strategic vision for market dominance.

One of the most frustrating aspects of my work is the added burden of being a penny stock and OTC company. In essence, companies that have made the jump to a national exchange have received at some level a review and participation by investment banks and their client institutions. Companies which have not gone through that process are always suspect from the perspective of Wall Street and other constituents. That translates directly to higher costs and closed doors. If the Company is going to show exponential growth, which is an essential part of our business plan, we need to kick open those doors.

We are arming ourselves with a battering ram. I intend to knock on those doors till the hinges come off and the path for our growth is wide open.

Good luck and good fortune to you and for all of us.

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

Kraig Labs Issues Letter to Shareholders in Advance of Annual Meeting

July 14th Letter to Shareholders in preparation for the Annual meeting

Dear Kraig Labs Family,

Last week we shared the news of the Company’s upcoming annual shareholder meeting to be held on July 24th. We have now completed the mailing of those notices, they should be arriving shortly. We have also made the notice and proxy voting card available on the Company website at www.kraiglabs.com/shareholder-meeting. If you do not receive a direct mailed notice it may be because your stock is held by a brokerage firm that received the notice. Please don’t worry, as you can still print and mail in the proxy card from the Company website to have your vote counted. We encourage all of our shareholders, who owned shares as of the record date, June 12, 2019, to complete and return their proxy voting card, regardless of whether you plan to attend the meeting in person or not.

As we look forward to the upcoming meeting and continue to work towards positioning the Company for the next stage of growth, we thought it appropriate to reflect on recently achieved major accomplishments and to share our immediate goals for our growth and expansion of our operations.

In the last 24 months the Company has transformed itself from a small R&D focused group to a company that management believes is on the verge of becoming the global supplier of spider silk materials. In this time we have:

Established Prodigy Textiles Ltd., our wholly owned Vietnamese subsidiary, which has been granted authorization and business licenses to open recombinant spider silk production operations.
Signed a development agreement with a market leader in high performance textiles, to create the next generation of non-woven protective fabrics using spider silk.
Secured a factory in Vietnam, to produce our recombinant spider silk, and signed agreements with suppliers and service providers to support growth.
Produced the first sample of woven Dragon Silk fabric.
Successfully completed a first of its kind, international shipment of transgenic silkworms.
Established and staffed the Company’s first standalone R&D headquarters.
Created new transgenics with the potential to surpass our existing technologies.
Implemented new processes rapidly accelerating the pace of new transgenic development.
Expanded our intellectual property position with additional provisional patent filings.
Implemented new production quality control systems in preparation for rapid expansion.

With all of these achievements secured, the Company now looks to the future and how best to serve our shareholders, and meet the market demand for our remarkable products. The expansion of our production operations will require capital, but we must be judicious in how we raise these funds.

On the financial front, the Company has operated for over 10 years in the “Over The Counter” market (OTC) and managed to prosper, despite the OTC’s significant limitations. Operating as an OTC company has limited our ability to raise capital from institutional investors, most of whom are prohibited by law, or charter, from investing in penny stock, or OTC companies.

In the past, we have faced significantly high costs for capital raised. We have been prevented from using more efficient and cost effective financing tools, which are available to firms listed on the national exchanges. Unlike many companies who flounder on the OTC, Kraig Labs has managed to survive by being judicious in how we have raised capital, a process that has forced us to limit growth and which has slowed our progress toward commercialization.

The shareholders of Kraig Labs have also faced challenges relating to our penny stock and OTC status. Many brokerage firms will not accept penny stocks and are prohibited from informing their clients about penny stock opportunities.

It is with this experience that we now believe the time has come to consider the possibility of raising the Company to a national exchange and freeing ourselves of the burden of being a penny stock. This move would provide access to institutional investment not currently available. Moving to a national exchange would lower the cost in raising the capital necessary to finance our growth. The move would also be designed to provide greater liquidity for our shareholders. The Board of Directors and management of Kraig Labs are committed to seeing our Company grow and we believe that the best path for this growth is to strengthen and reinforce our position as a publicly traded and publicly owned company by transitioning to a national exchange.

When the Company operated primarily as a small R&D operation, the burdens of being an OTC company were manageable, but, as we now move to commercialize our products and realize the potential of our technology, the time has come to start the next chapter by listing on a national exchange, a move that we believe will benefit the Company, all of our valued shareholders, and the global textile market.

The Company’s work to expand our corporate board, improve our financials, and strengthen corporate governance, including this shareholder meeting, have been a structured and methodical plan to meet the listing requirements for a national exchange, which include share price requirements. During the upcoming annual meeting we are bringing this vision to all of you, the Company’s stakeholders, to vote on this strategy to unlock the potential of our Company and power of our technology. We believe these moves will be a great benefit to our shareholders and our ability to capture a share of the global textile market.

After many years of measured and prudent moves, now is the right time for Kraig Labs to accelerate the next steps of our business model roll out and start the next chapter together.

Your voice and your vote are important; we encourage everyone to review all of the materials in the shareholder notice and to submit your proxy voting cards ahead of the annual meeting. Our recent growth, over the last 12 months, has created a possible opportunity to uplist. Let us move together and seize that opportunity.

Thank you for your ongoing support, and good luck to all of us as we move boldly into the future.

Kim Thompson

CEO

Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories awarded expanded investment license in Vietnam

ANN ARBOR, Mich., – July 11, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company has been awarded an increased investment license for expansion of its recombinant spider silk production at Prodigy Textiles, its Vietnamese subsidiary.

Under the new license, the Vietnamese government increased the Company’s potential investment cap, to as high as $50 million USD. This significantly increased investment limit will now allow the Company to prepare for the second phase expansion, planned for a 123 acre site located near Prodigy Textiles’ existing facility, and is part of the Company’s systematic and structured plan to expand capacity.

This new license was awarded during a recent trip to Vietnam, taken by the Company’s COO, Jon Rice, to oversee phase one production implementation. After reviewing the progress made under this first phase and meeting with Prodigy Textiles’ president, Vietnamese officials authorized the expansion of the Company investment in scaling up recombinant spider silk production.

“The granting of this expanded license is a demonstration of confidence in Kraig Labs and the potential our eco-friendly spider silk technology has to dramatically alter the global markets for silk and performance textiles,” said Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories to host annual shareholder meeting

ANN ARBOR, Mich., – July 8, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company will be holding its 2019 annual shareholder meeting on Wednesday, July 24, at 10 a.m. EDT, at the East Lansing Marriott at University place, located at 300 M.A.C. Ave, East Lansing, MI 48823. The proxy statement containing the meeting details is expected to be mailed no later than July 13 to shareholders of record as of June 12, 2019.

The shareholder meeting is an important step in positioning the Company to advance its business model, including the growth of its spider silk manufacturing operations.

Shareholders of record of Kraig Labs common stock and preferred stock, as the close of business on June 12, 2019, are entitle to notice of, and to vote at, the meeting.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news. More information on the shareholder meeting will be posted on the Company’s website in the next few days.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Management Travels to Vietnam to Oversee Prodigy Textiles Construction and Expansion

ANN ARBOR, Mich., – June 11, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that a senior member of its leadership team is travelling to Vietnam to oversee operations at the Company’s subsidiary Prodigy Textiles Ltd., construction at the Company’s new facility, and to coordinate the transfer of silkworms from the temporary facility into their permanent home. Management also anticipates meeting with provincial leaders to discuss further expansion of Prodigy Textiles production.

During this trip, a senior official from Kraig Labs plans to interview and select candidates for several key positions, including operational and financial leadership roles within Prodigy Textiles. Management has also set aside time to meet with its Vietnamese bankers to outline and discuss a collaborative agreement as Prodigy Textiles prepares to grow rapidly.

“Work at Prodigy Textiles has been moving quickly as we have continued to direct progress from our U.S. operations. It is now time for the Company to send someone back to Vietnam in order to oversee the hiring and filling of key positions as we build out our operational leadership team at Prodigy and transition to larger scale silk production,” said COO, Jon Rice. “I am excited to watch our international team grow as we work together bringing our environmentally sustainable, high performance textiles and yarns to the global markets.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com